Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04350580
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Groupe Hospitalier Universitaire Paris psychiatrie & neurosciences

Active Ingredients

Drugs in Phase 3 Trials (1)

immune globulin (human) (Gamastan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 3)

Respiratory Distress Syndrome (Phase 3)

Respiratory Distress Syndrome, Newborn (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1